• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Legal & Administration Lackey Melinda

    4/1/25 4:05:14 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCRT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lackey Melinda

    (Last) (First) (Middle)
    C/O ALAUNOS THERAPEUTICS, INC.
    2617 BISSONNET ST, SUITE 233

    (Street)
    HOUSTON TX 770005

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Alaunos Therapeutics, Inc. [ TCRT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Legal & Administration
    3. Date of Earliest Transaction (Month/Day/Year)
    03/29/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $1.46 03/29/2025 A 1,000 (1) 03/28/2035 Common Stock 1,000 $0 1,000 D
    Explanation of Responses:
    1. One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 29, 2025, with the first vesting occurring on June 29, 2025 subject to the Reporting Person's continued service through each vesting date.
    /s/ Melinda Lackey 03/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TCRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRT

    DatePrice TargetRatingAnalyst
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $TCRT
    Financials

    Live finance-specific insights

    See more
    • Alaunos Therapeutics Reports First Quarter 2023 Financial Results

      Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce

      5/10/23 7:00:17 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

      HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici

      5/3/23 8:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

      HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at

      2/28/23 4:01:07 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

      Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

      10/4/22 7:18:05 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

      HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring

      3/30/23 7:00:40 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

      HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion. "Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team," commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "He joins Alaunos at an exciting time as we continue to advance development of our promising TCR T Library

      8/4/22 5:00:00 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

      SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,

      4/7/22 11:42:00 AM ET
      $TCRT
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024 HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Compan

      11/14/23 7:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic repriori

      8/14/23 4:05:34 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

      HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company's TCR-T therapy in solid tumors targeting specific, cancer-driving mutations currently being evaluated in a Phase 1/2 open-label, dose-escalation trial at The University of Texas MD Anderson Cancer Center. Details of th

      6/29/23 7:00:53 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alaunos Therapeutics Inc.

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      11/14/24 4:06:27 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/14/24 12:43:20 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/13/24 4:58:29 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Alaunos Therapeutics Inc.

      PRE 14A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      5/9/25 9:09:41 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Alaunos Therapeutics Inc.

      10-K/A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      4/30/25 4:59:30 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      4/18/25 4:45:08 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:42:09 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Weis Holger

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:33:33 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vieser Jaime was granted 17,465 shares, increasing direct ownership by 67% to 43,359 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:26:04 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care